Veozah (fezolinetant) was approved in 2023 by the FDA to treat moderate to severe hot flashes. A similar drug, elinzanetant, ...

Market is projected to reach a multimillion-dollar valuation by 2034, driven by an unexpected compound annual growth rate (5.64) from 2025 to 2034.

Awareness Month, which seeks to raise recognition and push for research of this rare genomic imprinting disorder. PWS is estimated to affect about one in 20 000 individuals1 yet, until now, people ...

“Can’t Look Away” is currently streaming on Jolt, an AI-driven streaming platform that connects independent films with ...

In today's Pharmalittle roundup, we're reading about HHS canceling a Moderna contract, FDA rejecting a rare disease drug, and ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

High levels of cholesterol may gradually clog your arteries, which makes it more difficult for blood to flow. This increases the likelihood of high blood pressure, heart attack, and stroke if not ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...

Qure divested for $25M, advanced AMT-130 with FDA approvals, and building infrastructure. A strong balance sheet backs ...

According to a new market research report titled "Green Ammonia Market: Size & Forecast by Technology (Alkaline Water Electrolysis, PEM Electrolysis), Production Method (Haber-Bosch with Green ...

Rollout plans for the company’s early dementia detection software in the US follow the tool’s FDA clearance in January 2025.

The recent Colorado Supreme Court decision of People v. Beverly whittled legislation enhancing the penalty for the ...